-
News | 2021.03.11
2019-2023 Strategic Plan: Two new projects to boost the Institut Pasteur Innovation Accelerator
Two projects have been accepted into the Institut Pasteur Innovation Accelerator, an initiative to improve the development potential of the Institut Pasteur's research: a highly automated technological system involving bioassays and a partnership based on a French startup studio. The Institut Pasteur will be setting up the project Pfbioassays [in French] (Thierry Rose and Sébastien...
-
Article | 2019.06.25
Novel approaches to diagnosis, vaccination and therapy (12 entities)
This thematic area gathers investigators with a common interest in translational research. It addresses the design, development and evaluation of candidate vaccines, therapeutics, diagnosis tools, and immunotherapies, for conversion of scientific breakthroughs into improved human health.
-
News | 2025.05.30
Deep Tech Venture Builder: the project PICASSO from the Institut Pasteur joins EIT Health program
Specifically designed to support academic teams with deep tech solutions, EIT Health’s DTVB provides start-ups with the right support to overcome the most frequent hurdles experienced when launching to market. Notoriously known as the “Valley of Death” – where many promising ideas fail to transition out of academic environments – successfully navigating this stage requires overcoming the most...
-
News | 2022.06.14
A New Drug Target against Malaria
Malaria is a disease that continues to cause tremendous suffering and mortality in the tropics. This disease is caused by Plasmodium parasites. The species Plasmodium falciparum causes the severest and most deadly form of malaria. Scientists from Institut Pasteur studied the blood stage of the parasites and found a mechanism which could lead to new and efficient drugs against Malaria.Despite...
-
Document de presse | 2014.09.09
Highly regulated therapeutic target shows promise in the search for new antimalarial treatments
Artemisinin is currently the most effective malarial treatment available. However, the recent emergence in South-East Asia of artemisinin-resistant parasites strengthens the urgent need to identify a new generation of antimalarial drugs. In this context, scientists at the Institut Pasteur and CNRS have determined the three-dimensional structure of a promising new therapeutic target for malaria:...
-
Document de presse | 2013.10.09
Fine-tuning the approach to malaria and toxoplasmosis research
A study carried out by teams from the Institut Pasteur, the Institut Cochin (Inserm, CNRS, Paris Descartes University), and the Wellcome Trust Centre for Molecular Parasitology at the University of Glasgow, may very well redefine current approaches to malaria and toxoplasmosis research in terms of treatment development. Their research which focuses on the role played by the protein AMA1 (present...
-
News | 2019.06.14
Ceremony for the 2019 Pasteur Vallery-Radot Prize (awarded by the BnF)
The National Library of France (BnF) has awarded the 2019 Pasteur Vallery-Radot Prize to Institut Pasteur scientists Guillaume Duménil and Rogerio Amino. The winners were invited by BnF President Laurence Engel to receive their awards on June 13, 2019, at a ceremony held in the BnF Richelieu Library and attended by Daniel Louvard, a member of the French Academy of Sciences, and Stewart Cole,...
-
Fiche maladie | 2021.05.11
Parkinson
Parkinson’s disease is a degenerative disorder affecting almost 200,000 people in France. It is the second leading cause of motor disability in adults after stroke and is characterized by the gradual loss of certain neurons in the brain. Although current treatments may alleviate symptoms, they are incapable of slowing disease progression.
-
Document de presse | 2024.01.05
The Institut Pasteur and Sensorion announce that their partnership to accelerate gene therapy programs targeting hearing disorders has been extended for five years
The framework extension agreement underlines the successful collaboration between Sensorion and the Institut Pasteur, involving the Hearing Institute, a research center of the Institut Pasteur, focused on the development of gene therapy programs Two gene therapy development programs are currently being conducted under this agreement, including SENS-501 (OTOF-GT) and GJB2-GT. Sensorion submitted a...
-
News | 2016.11.16
The Institut Pasteur of Iran held the 2016 MATI Regional Meeting of the Institut Pasteur international Network
100 participants were gathered from 7th to 9th November 2016 at the Institut Pasteur of Iran for the MATI Regional Meeting (Morocco, Algeria, Tunisia and Iran) of the Institut Pasteur International Network.The meting was opened by Pr. Hassan Hashemi, Minister of Health of the Islamic Republic of Iran, Pr. Mostafa Ghanei, Director of the Institut Pasteur of Iran, Mr. François Sénémaud,...